Biohaven Pharmaceutical
Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Launch date
Employees
Market cap
$3.6b
Enterprise valuation
$3.2b (Public information from Sep 2024)
Share price
$39.4 BHVN
New Haven Connecticut (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 10.0m | 16.0m |
| % growth | - | - | - | - | - | - | 60 % |
| EBITDA | - | (114m) | (218m) | (567m) | (429m) | - | - |
| Profit | - | (119m) | (214m) | (570m) | (408m) | - | - |
| EV / EBITDA | - | -48.7x | -45.5x | - | - | - | - |
| R&D budget | - | 98.5m | 181m | 437m | 373m | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
* | N/A | N/A | IPO |
* | $450m | Post IPO Equity | |
* | $11.6b Valuation: $11.6b -53.3x EV/LTM EBITDA | Acquisition | |
* | N/A | $225m | Post IPO Equity |
* | N/A | $230m | Post IPO Equity |
| Total Funding | - | ||
